MoonLake Immunotherapeutics 뉴스 - MLTX | 주식 나스닥

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

프리미엄

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN...

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

MoonLake Immunotherapeutics to host a Capital Markets Updateon Wednesday, September 11 ZUG, Switzerland...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets...

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase...

Form 4 - Statement of changes in beneficial ownership of securities

Sleeping
Come on 70.00

👍️0

Monksdream 2 년 전

MLTX new 52 week high

👍️0

AKATITUS 2 년 전

Haha. Now that's funny. 18,000 share buy at 52.00 dollars.

👍️0

AKATITUS 2 년 전

Damm some big buys at 54.00 WoW

Looks like a good churning. Will tomorrow be the same. ??????

👍️0

MiamiGent 2 년 전

MLTX Started the day with a bang. Falling back, presently

MOONLAKE IMMUNOTHERAPEUTICS
$41.80 +15.92 (+61.51%)
As of Jun-26-202310:46:16 AM ET

https://stockcharts.com/h-sc/ui?s=MLTX

Wolfspeed, Genesco, PacWest Bancorp And Other Big Stocks Moving Higher On Monday
BENZINGA
31 mins ago
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 60 points on Monday. Here are some big stocks recording gains in today's session.

MoonLake Immunotherapeutics (NASDAQ:MLTX) jumped 75% to $45.50 after the company's Phase 2 study for Nanobody sonelokimabint met its primary endpoint in hidradenitis suppurativa.

(con't)

👍️0

AKATITUS 2 년 전

So pissed I was trying to sell somethings to buy 40ts them boom 100 bucks F##########

MoonLake Immunotherapeutics (NASDAQ: MLTX) 10% owner Bihua Chen acquired a total of 5,635,000 shares at an average price of $10.00. To acquire these shares, it cost around $28.5 million.

👍️0

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

MoonLake Immunotherapeutics (MLTX)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

MLTX 뉴스

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Form 4 - Statement of changes in beneficial ownership of securities

MLTX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기

시장 데이터

뉴스

도구

시장

팔로우

Hot Features

피드 팔로우

실시간 옵션 플로우

모니터

MoonLake Immunotherapeutics (MLTX) 뉴스

MoonLake Immunotherapeutics (MLTX)

실시간 스트리밍 인용문, 아이디어 및 실시간 토론을 위한 허브

MLTX 뉴스

MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab

Form 8-K - Current report

MoonLake Immunotherapeutics starts Phase 3 IZAR program of the Nanobody® sonelokimab in patients with active psoriatic arthritis

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

MoonLake Immunotherapeutics to host a Capital Markets Update on Wednesday, September 11

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

Form 8-K - Current report

MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis

Form 4 - Statement of changes in beneficial ownership of securities

MLTX Discussion

최근 히스토리

회사 소개

사업

Popular

앱 받기